[Ochrobactrum anthropi bacteremia in a child with cystic fibrosis].
Yagüe-Muñoz
Alberto
A
Gregori-Roig
Pascual
P
Valls-López
Sonia
S
Pantoja-Martínez
Jorge
J
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications / Q000382:microbiology*; D055499:Catheter-Related Infections / Q000150:complications / Q000382:microbiology*; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002648:Child; D002764:Cholecystitis / Q000150:complications / Q000382:microbiology; D003550:Cystic Fibrosis / Q000150:complications*; D004198:Disease Susceptibility; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000382:microbiology*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020621:Ochrobactrum anthropi / Q000302:isolation & purification*; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014031:Tobramycin